Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

GEO-CM04S1 Demonstrates Superior T Cell Responses Compared to mRNA Vaccine in Phase 2 Trial Among Immunocompromised Patients ...

Prof. Musallam’s recognition by EHA affirms his role as a transformative figure in hematology and underscores the UAE’s growing influence in global medical research. His work continues to inspire a ...

Congress, held from June 12 to June 15 in Milan, Italy, updated results from the Phase II registrational iMMagine-1 study ...

Bristol-Myers Squibb Company (NYSE: BMY) is one of the best stocks to buy for beginners now. On June 12, Bristol Myers Squibb ...

First clinical data for INCA033989, a novel monoclonal antibody from Incyte (Nasdaq: INCY) targeting CALR-mutant ...

A compelling session at the EHA Congress explored how space research is reshaping our understanding of hematologic processes.

Congress, hematology experts highlight breakthroughs in treatment, the importance of patient voices, and challenges in making innovations accessible worldwide.

The lack of therapeutic precision in treatment of myeloid malignancies is in sharp contrast with the fact that myeloid cancers represent the perhaps best characterized cancers of all at the cellular, ...

Experts reassess endpoints, patient selection, targets, and timing for the development of successful immune-based treatments ...

During the trial, none of the participants needed blood transfusions, and 92.7% of them reached Hb levels of at least 12g/dL.

A combination therapy that adds a recently approved drug to the current standard of care for newly diagnosed acute myeloid ...